http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20050017001-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 |
| filingDate | 2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20050017001-A |
| titleOfInvention | Azolidinone-vinyl fused-benzene derivatives |
| abstract | The present invention relates to formula (I) for the treatment and / or prevention of autoimmune diseases and / or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney disease, platelet aggregation, cancer, graft rejection or lung damage. It relates to azolidinone-vinyl conjugated-benzene derivatives. Formula (I) wherein A, X, Y, Z, R 1 , R 2 and n are as described in the detailed description of the invention.n n n (I) |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210084281-A |
| priorityDate | 2002-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1094.